Clinical Trial Update: Vortioxetine as a Novel Anti-depressant With Improvement in Cognitive Abilities [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for vortioxetine as a novel antidepressant showing improvement in cognitive abilities.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Vortioxetine (vortioxetine)

Snippet

Sponsor: Scotmann Pharmaceuticals | Conditions: Major Depressive Disorder | Phase 3 | Status: UNKNOWN